Close Menu

NEW YORK (GenomeWeb) – Myriad Genetics and other patent owners have settled their BRCA testing patent lawsuit with Pathway Genomics and Invitae.

Myriad sued Pathway on June 13, 2014, for infringement of its patent claims underlying BRCA1 and BRCA2 genetic testing. The legal tussle began soon after Pathway launched a next-generation sequencing test for gauging alterations in BRCA1 and BRCA2 genes, called BRCATrue.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.